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ABSTRACT 
 
Thyroid hormones (THs) control the adipose tissue development and metabolism. They regulate 
both adipocyte proliferation and differentiation and, as they cause weight loss by increasing the 
metabolic rate, may be useful for obesity treatment. However, due to their cardiotoxic effects, 
like tachycardia and arrhythmia, their use is limited to hypothyroid obese patients. Some TH 
metabolites have been recently shown to possess the same beneficial metabolic effects as THs 
without the same negative effects. A biogenic amine named 3-Iodothyronamine (T1AM), i.e., is 
an endogenous compound derived by thyroxine (T4) deiodination and decarboxylation that 
affects carbohydrate and lipid metabolism without undesirable side effects. T1AM exhibits 
cardiac effects opposite to those associated with thyroid hormones, like bradycardia in mice, and 
in isolated working rat heart, it produces a rapid, reversible, dose-dependent decrease in cardiac 
output, aortic pressure and coronary flow. These findings suggest that T1AM produces a negative 
inotropic and chronotropic effect. 
Intraperitoneal injections of T1AM also induce reduction of RQ from 0.9 to 0.7, both in mice and 
Djungarian hamsters. This indicates that carbohydrate utilisation is reduced in response to T1AM 
and energy requirements are covered by lipid utilisation. Interestingly, the complete RQ shift is 
reached 4.5 h after the T1AM injection and persists at least for 24 hours. Ketone bodies in the 
urine and the significant loss of body fat mass confirm that lipids are predominantly used to 
cover the energy requirements in response to T1AM administration. 
The molecular mechanisms by which T1AM favours lipid than glucose catabolism are not 
known, but changes in gene expression can be hypothesized, given the delayed and long lasting 
phenotypical effects of T1AM.  
To verify this hypothesis we analyzed by microarrays the gene expression profiles in 
subcutaneous adipose tissues of eight rats chronically treated with T1AM as compared with eight 
untreated rats.  
Many genes linked to lipid metabolism, adipogenesis and angiogenesis appeared affected by 
chronic administration of T1AM, thus explaining, at least in part, the T1AM phenotypic effects 
observed in rodents. Furthermore, T1AM influenced the expression of several genes relating to 
lipoprotein metabolism that provide new insights on T1AM mechanism of action, like, i.e., the 
regulation of cholesterol homeostasis. 
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INTRODUCTION 
 
Thyroid hormones (THs) control the adipose tissue development and metabolism (Viguerie et al. 
2002). They regulate adipocyte proliferation and differentiation (Hauner et al. 1989, Darimont et 
al. 1993) and, as they cause weight reduction loss by increasing the metabolic rate, may be 
indicated for obesity treatment (Krotkiewski 2002). Their use, however, is limited because they 
produce thyrotoxic effects including cardiotoxic effects like tachycardia and arrhythmia 
(Krotkiewski 2002). The identification of TH analogs that retain anti-obesity efficacy with a few 
undesirable side effects is therefore an important research goal. Some TH metabolites have been 
recently shown to possess the same beneficial metabolic effects as THs without the same 
negative effects. The biogenic amine 3-Iodothyronamine (T1AM) for example, affects 
carbohydrate and lipid metabolism without undesirable side effects (Chiellini et al. 2007, 
Braulke et al. 2008). Scanlan and collaborators by using synthetic T1AM as a standard in liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) assay, demonstrated that T1AM is an 
endogenous component of biogenic amine (Scanlan et al. 2004). It has been detected in rat serum 
and tissues as well in human and Djungarian hamster blood (Braulke et al. 2008, Saba et al. 
2010). The quantitative analysis of its physiological concentration has indicated that T1AM 
content is higher in organs than in blood suggesting that some tissues are able to accumulate it 
(Saba et al. 2010). 
 
1. T1AM 
1.1. T1AM BIOSYNTHESIS 
The pathway of endogenous T1AM biosynthesis is still unknown. It has been suggested that 
T1AM derives from THs through decarboxylation and deiodination (Scanlan et al. 2004). 
Although the iodothyronine-decarboxylating enzyme has not been still identified (Wu et al. 
2005). T1AM might be formed by decarboxylation of T4 and rT3, to T4AM and rT3AM 
respectively. T4AM is a good substrate for Dio3 and is deiodinated to rT3AM. The sequential 
deiodination of rT3AM by Dio1 and Dio2 produces T1AM (Piehl et al. 2008) (figure 1). However, 
no direct evidence of T4 or T3 conversion to T1AM is known at present.  
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Figure 1. Pathways suggested for T1AM biosynthesis. Diagonal arrows, deiodination reactions catalyzed by 
deiodinases . Horizontal arrows, putative decarboxylation reactions that might represent the first step of T1AM 
biosynthesis. 
 
1.2. T1AM METABOLISM 
T1AM is substrate for sulfotransferases (SULTs) and SULT1A2, SULT1A3 and SULT1E1 show the 
highest activity toward T1AM. It has been hypothesized that SULT action reduces and regulates 
the T1AM effects (Pietsch, Scanlan and Anderson 2007). In 2009, Wood and colleagues 
demonstrated that T1AM is susceptible to oxidative deamination of the ethylamine side chain by 
an amine oxidase that converts it in thyroacetic acid (TA1) whose biological activity is unknown 
(Wood et al. 2009). 
 
1.3. T1AM RECEPTORS 
The G protein-coupled trace amine-associated receptor 1 (TAAR1) is the first molecular target 
suggested to mediate the T1AM effects. T1AM induces the synthesis of cAMP in HEK-293 cells 
stably transfected  with rat TAAR1 (Scanlan TS et al.,  2004). However, T1AM also inhibits the 
cAMP synthesis through the interaction with the α2A adrenergic receptor  (Adra2A), a Gαi coupled 
receptor expressed in many cell types (Regard et al. 2007). Both these receptors interact with 
T1AM and the final effect depends on TAAR1/ Adra2A ratio.  
T1AM, moreover, inhibits vesicular monoamine transporter (VMAT2), an intracellular 
transporter that packages monoamine into synaptic vesicles. This observation is suggestive of a 
neuromodulatory role for T1AM (Snead et al. 2007). 
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1.4. T1AM INTRACELLULAR TRANSPORT 
T1AM has been recently found to be largely bound to the apoB-100-containing lipoproteins in 
human serum. It reversibly binds the apoB-100-containing lipoprotein with an equilibrium 
dissociation constant of 17 nM and T1AM /apoB-100 stoichiometry of 1:1. This binding is highly 
selective for T1AM and increases its intracellular uptake significantly (Roy, Placzek and Scanlan 
2012).  
A 2009 study demonstrated that the intracellular transfer of T1AM occurs in multiple cell lines 
and involves a specific mechanism of transport that can be saturated and inhibited. T1AM 
transport is independent from sodium and chloride and is driven by an outwardly directed proton 
gradient. By using a library of siRNA against the entire solute carrier (SLC) superfamily of 403 
transporter genes, eight putative T1AM  transporters were identified. These transporters 
collectively participate in the regulation of T1AM intracellular levels  (Ianculescu, Giacomini 
and Scanlan 2009).  
T1AM uptake is also mediated by  non-SLC transporters or by receptor-mediated endocytosis 
(Lin and Scanlan 2005).  
 
1.5. T1AM EFFECTS 
Intraperitoneal (ip) injections of T1AM in C57BL/6 wild-type mice or Djungarian hamsters 
induce numerous effects like bradycardia, hypothermia, hyperglycemia, decrease of metabolic 
rate (VO2), reduction of respiratory quotient (RQ), ketonuria and loss of fat mass (Scanlan et al. 
2004, Braulke et al. 2008, Regard et al. 2007) (table 1). In Djungarian hamsters, the injection of 
50mg T1AM/kg leads to a 10-fold increase of T1AM blood concentration, from 6 nM to 56 nM, 
(Braulke et al. 2008) whose origin is unclear whether is pharmacological or physiological. 
Most of T1AM effects are detected within minutes after the injection. The bradycardia, 
hyperglycemia, hypothermic and hypometabolic state reach a maximum in 1-2 h, while the 
complete RQ shift is reached 4.5 h after the T1AM injection. Afterwards, heart activity, 
metabolic rate, body temperature and blood glucose levels return to baseline values within 6-8 h, 
while the reduced RQ persists for at least 24 h. Ketonuria and the loss of fat mass appear and 
revert much later (Scanlan et al. 2004, Braulke et al. 2008, Regard et al. 2007). 
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Table 1. Summary of the T1AM effects. ↑, Increase; ↓, Reduction. 
 
1.5.1 Hypothermic and hypometabolic state 
After T1AM injection into C57BL/6 wild-type mice and Djungarian hamsters body temperature 
and metabolic rate decrease within minutes. The body temperature falls from 37 to 31°C within 
30 min and 90 min later it drops to 29.5°C. The metabolic rate, measured as decrease in VO2, 
declines from 2.5 to 1.8 ml/gh within 5 min. Both these effects are reversible: the animals 
recover from hypothermia and hypometabolism 6-8 h after the T1AM administration (Braulke et 
al. 2008, Scanlan et al. 2004). Noteworthy, the hypothermia is preceded by the decrease in 
metabolic rate and the hypothermic effect is interpreted as a result of the reduced metabolic rate 
(Braulke et al. 2008). 
 
1.5.2 Negative chronotropy and inotropy 
The administration of T1AM to C57BL/6 wild-type mice induces reversible bradycardia: the 
heart rate drops from 600 to 350 beats per minute and reverts to normal 6-8 h after the injection 
(Scanlan et al. 2004). In isolated working rat hearts perfused with increasing T1AM 
concentrations, the heart rate decreases within minutes to an  IC50 of 37 µM. It also causes the 
fall of cardiac output to an  IC50 of 29 µM. Both these effects persist for the whole duration of the 
perfusion and revert to normal by removing T1AM (Chiellini et al. 2007). 
These findings suggest that T1AM produces a negative inotropic and chronotropic effect. 
T1AM also inhibits other cardiac parameters including the aortic pressure and the coronary flow 
(Chiellini et al. 2007). 
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1.5.3 Hyperglycemia 
In 2007 Regard and colleagues observed that T1AM acts as a regulator of insulin secretion 
(Regard et al. 2007). The ip administration of 50mg/kg of T1AM, in fact, increases blood glucose 
levels in C57BL/6 wild-type mice. This effect is detectable within minutes after the injection, 
reaches a maximum of 250% of the basal value 2h after the treatment and reverts 8 h later. It is 
accompanied by a decrease in blood insulin levels and an increase in blood glucagon levels. The 
administration of insulin normalizes the blood glucose levels, indicating that peripheral tissues 
remain sensitive to insulin during the T1AM treatment (Regard et al. 2007). According to these 
findings T1AM has been observed to inhibit the release of insulin from primary murine and 
human pancreatic ß-cells in vitro (Regard et al. 2007). 
More recently it has been reported that intracerebroventricular (icv) infusion of a 100-fold lower 
dose of T1AM (0.5mg/kg) produces even more pronounced effects on peripheral glucose 
metabolism in male Wistar rats (Klieverik et al. 2009). 
 
1.5.4 Reduction of the respiratory quotient, ketonuria and loss of fat mass 
In both C57BL/6 wild-type mice and Djungarian hamsters, an ip injection of T1AM induces a 
reduction of RQ from 0.9 to 0.7 (Braulke et al. 2008). This indicates that the utilisation of 
carbohydrates is suppressed in response to T1AM and that the energy requirements are covered 
by lipid consumption (Braulke et al. 2008). Interestingly, the complete RQ shift is reached 4.5 h 
after the injection and persists for at least 24 h (Braulke et al. 2008). The presence of ketone 
bodies in the urine and the significant loss of body fat mass confirm the assumption that lipids 
are predominantly used to cover the energy requirements in response to T1AM treatment 
(Braulke et al. 2008). 
 
1.5.5 Other effects  
Dhillo and colleagues demonstrated that T1AM affects the food intake (Dhillo et al. 2009). 
Several hypothalamic nuclei like the paraventricular nucleus and arcuate nucleus are important 
regulators of food intake and energy balance. Given that T1AM is present in the brain and 
TAAR1 is expressed in the hypothalamic nuclei these authors hypothesized that T1AM plays a 
role in regulating the energy homeostasis. They observed that ip or iv injections of low doses of 
T1AM (4 and 1.2 µmol/kg, respectively) induced food intake without affecting the metabolic rate 
and the locomotor activity in rats and mice (Dhillo et al. 2009). However, at higher doses of 
T1AM (50mg/kg) the authors confirmed the previously reported reduction of oxygen 
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consumption and locomotor activity (Braulke et al. 2008). In addition, T1AM injected directly 
into the arcuate nucleus of rodents caused a 3-fold increase in food intake, suggesting that T1AM 
is an orexigenic compound that acts through the arcuate nucleus to increase the food intake 
(Dhillo et al. 2009). 
In hypothyroid rats T1AM produces relevant effects on O2 consumption and ROS production by 
liver mitochondria. In particular, T1AM reduces oxygen consumption in mitochondria and 
increases H2O2 release. This suggests that the electron flow rate along the respiratory chain 
decreases in presence of T1AM (Venditti et al. 2011). 
 
2. GENE EXPRESSION MICROARRAY 
The microarray technology, introduced in 1995 by a research group of Standford University 
(Schena et al. 1995), is a highthroughput technology which provides a global view of gene 
expression patterns in biological samples. By the simultaneous evaluation of the expression 
levels of thousands of genes, the microarrays allow users to compare two biological samples 
(normal VS pathological or treated VS control sample) in order to obtain information on the 
molecular mechanisms responsible for their phenotype. 
On a solid surface thousands of single strand oligonucleotide sequences (probes) are 
immobilized, ready to hybridize to complementary sequences (targets) extracted from the 
biological samples of interest. Each gene is represented by thousands of identical probes within a 
feature (spot) and a single microarray contains up to tens of thousands of spots (Figure 2). 
 
 
Figure 2. Schematic representation of a microarray slide. A microarray consists of multiple features (spots). Each 
spot  is representative of a gene and contains thousand of identical probes (yellow helices).  
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In a typical dual-color microarray experiment total RNA is extracted from the two samples to be 
compared. The RNA is converted in cDNA by reverse transcription polymerase chain reaction. 
The cDNA of each sample is then labelled with a different fluorescent dye, for example one with 
Cy3 (green) and the other with Cy5 (red). The two labelled cDNAs are mixed in the same 
quantity and deposited on the microarray slide. After an overnight incubation the sequences of 
labelled cDNAs (targets) hybridize to complementary sequences attached on the array (figure 3). 
 
 
Figure 3. Schematic representation of a dual-color microarray experiment. 
 
The scanning of the microarray surface with a double laser scanner enables to highlight the 
fluorescent spots and produces two images. In the first image the Cy3 fluorescence is displayed 
as green and in the second the Cy5 fluorescence is displayed as red (figure 4). The overlapping of 
the two images produces a single image that is processed to subtract the background 
fluorescence and to normalize the obtained data.  
The measured red and green fluorescence intensities for each spot are proportional to the amount 
of mRNA, corresponding to a specific transcript, expressed by the two compared samples. 
For each spot the two fluorescence intensities are translated into numerical values whose ratio 
indicates the difference in the expression of each gene between the two samples. A statistical 
analysis is then performed to identify those genes whose differential expression is statistically 
significant between the two samples of interest. 
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Figure 4. Image acquisition of dual-color microarray. The double laser scanner performs a double scanning and 
produces two distinct images for each fluorescent dye. The two images are overlapped to obtain a single image. 
 
3. AIM OF THE STUDY 
T1AM slows down the metabolism by blocking carbohydrates utilisation and promoting lipid 
consumption. The molecular mechanisms by which T1AM favours the lipid catabolism over 
glucose catabolism is not known. As the T1AM effects on fatty acid metabolism outlast all the 
other effects (bradycardia, hyperglycemia, hypothermia and hypometbolism) it is reasonable to 
expect that the regulation of energy utilization by T1AM derives from changes in gene 
expression. To verify this hypothesis we used the microarray technology and analyzed gene 
expression profiles in the adipose tissue of rats chronically treated with T1AM as compared to 
untreated rats.  
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MATERIALS AND METHODS 
 
ANIMALS AND T1AM TREATMENT 
The animals used in this study were male Wistar rats. Prior to any experimental manipulation the 
rats were acclimatized for one week in the animal house facility at the Human and 
Environmental Science Departement of Pisa University. 
The project was approved by the Animal Care and Use committee of the University of Pisa.  
Eight rats of about 100–125 g body weight were treated with T1AM by intraperitoneal injection 
of 10 mg /Kg twice a day for five days. Eight control rats were treated with T1AM free-
intraperitoneal injection under parallel housing conditions.  The rats were sacrificed by guillotine 
and the subcutaneous adipose tissue was immediately removed. The tissue samples were flash-
frozen and stored at -80°C until their use.   
 
ISOLATION, AMPLIFICATION AND LABELLING OF RNA  
Total RNA was isolated from adipose tissues by the RNeasy Lipid Tissue Mini kit (Qiagen, 
Valencia, CA, USA). 
Residual DNA was eliminated by on-column DNase digestion using the RNase-Free DNAase 
Set (Qiagen, Valencia, CA, USA). 
The quantity and purity of total RNA were measured by 260 nm UV absorption and by 260/280 
ratio, respectively, using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). All RNAs displayed a 260/280 optical density ratio ≥1.9.  
The RNA integrity was checked with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo 
Alto, CA, USA) using the Agilent RNA 6000 Nano kit (Agilent Technologies, Palo Alto, CA, 
USA). All RNAs displayed a RNA Integrity Number (RIN) ≥8.  
One microgram of total RNA from treated and control animals was amplified and labelled with 
Cyanine 5 (Cy5) and Cyanine 3 (Cy3) dyes (Agilent Technologies, PaloAlto, CA, USA), 
respectively, by the Quick-Amp Labeling kit (Agilent Technologies, Palo Alto, CA, USA). In 
order to monitor the experiment, from sample amplification and labelling to microarray 
hybridization, a RNA Spike-In (Agilent Technologies, PaloAlto, CA, USA) was added to each 
RNA sample. 
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The Cy3 and Cy5 dye incorporation rates were measured by UV absorption at 555 nm and 647 
nm, respectively. 
Both fluorophores showed a comparable incorporation efficiency ranging between 11 and 15 
pmol of dye per µg of amplified RNA.  
 
MICROARRAY HYBRIDIZATION 
The hybridization mixture containing 825 ng of Cy3-labelled amplified RNA (corresponding to 
9-10 pmol of Cy3 dye), 825 ng of Cy5-labelled amplified RNA (corresponding to 11-12 pmol of 
Cy5 dye), 11µl of 10X Blocking Agent, 2.2 µl of 25X fragmentation buffer and 55 µl of 2X GE 
hybridization buffer (the last three from the Gene Expression hybridisation kit plus, Agilent 
Technologies, Palo Alto, CA, USA) was hybridized to Whole Rat Genome Oligo Microarrays 
4x44K (Agilent Technologies, Palo Alto, CA, USA). Each slide contains 4 arrays with 44,000 
60-mer oligonucleotide probes representing 41,012 unique probes. 
The array hybridisation was performed at 65°C in the Agilent oven (Agilent Technologies, Palo 
Alto, CA, USA) for 17 h under constant rotation. After hybridisation, the arrays were washed 
following the Quick Amp Labeling protocol (Agilent Technologies, Palo Alto, CA, USA). To 
prevent the ozone-mediated fluorescent signal degradation, the arrays were immersed in 
Acetonitrile solution (Sigma-Aldrich, St.Louis, MO, USA) for 10 sec and successively in 
Stabilization and Drying solution (Agilent Technologies, Palo Alto, CA, USA) for 30 sec.  These 
last two washes were performed at room temperature. 
 
MICROARRAY EXPERIMENTAL DESIGN 
A balanced block design was applied: on each array, two differently labelled samples from the 
treated and the control groups were hybridized, for a total of eight arrays (figure 5). 
 
Figure 5. Balanced Block experimental design. 
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MICROARRAY DATA ACQUISITION AND ANALYSIS 
Microarray images were acquired by the Agilent scanner G2565BA (Agilent Technologies, Palo 
Alto, CA, USA) at 5µm resolution and intensity raw data were extracted by the software Feature 
Extraction V10.5 (Agilent Technologies, Palo Alto, CA, USA). 
Data preprocessing and statistical analysis were performed by LIMMA (LInear Model of 
Microarray Analysis) package (Smyth 2005). The intensity raw data were background subtracted 
by the normexp method and normalized within-arrays with the LOESS and between-arrays with 
the scale methods, respectively.  
For the statistical analysis, the bayesian moderated t-statistic (Smyth 2004) was used and only 
genes with Benjamini and Hochberg (Benjamini and Hochberg 1995) adjusted-p-value < 0.01 
were considered as differentially expressed. 
 
Pathway-Express was used to map the differentially expressed genes in KEGG pathways 
(http://vortex.cs.wayne.edu/projects.htm#Pathway-Express) (Draghici et al. 2007). GeneCards® 
(http://www.genecards.org) (Safran et al. 2003), Onto-Express 
(http://vortex.cs.wayne.edu/ontoexpress/)  (Draghici et al. 2003, Khatri et al. 2002), PubGene 
(http://www.pubgene.org/) (Jenssen et al. 2001) and Coremine 
(http://www.coremine.com/medical/ ) were used to perform an accurate screening of the 
scientific literature concerning the differentially expressed genes. 
 
MICROARRAY DATA VALIDATION BY RT-QPCR 
The same RNA samples used in the microarray experiment were used to perform the RT-qPCR 
experiments. Total RNAs were reverse transcribed with random and oligo-dT primers by the 
QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA, USA). PCR primers were designed 
by the Beacon Designer 4.0 software (Premier Biosoft International, Palo Alto, CA, USA) and 
synthesized by Sigma-Aldrich (Sigma-Aldrich, St.Louis,  MO, USA ). The primer sequences are 
listed in table 2. 
RT-qPCR was performed by the iCycler iQ instrument (Biorad, Hercules, CA, USA) using the 
iQ SYBR Green Supermix (Biorad, Hercules, CA, USA). The amplification protocol was: 3 min 
at 95°C (DNA polymerase activation), then 40 cycles at 95°C per 30s (denaturation step), 58–
62°C (depending on primer Tm) per 60s (annealing step) and 72°C per 30s (extension step). 
Afterwards, a gradual increase in temperature from 55°C to 95°C at 0.5°C/10s was utilized to 
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build a melting curve. For each primer pair, the amplification efficiency was tested using five 
serial dilutions of cDNA carried out in duplicate. To reduce the effects of the biological variation 
on the amplification efficiency, a cDNA sample obtained by pooling the RNAs from all the eight 
control samples was used. For all the primer pairs the amplification efficiency was between 90 
and 110% and the square regression coefficient (r2) was >0.99. The stability of six housekeeping 
genes (Mapk6, Kdm2b, Psmd4, Cypa, B2mg, Bact) was evaluated by using geNorm software 
(Vandesompele et al. 2002). geNorm identified three housekeeping genes (Psmd4, Cypa and 
B2mg) as stable (M<1.5 and V3/4<0.114), which were used to normalize the expression values of 
the target genes. 
Each sample was run in triplicate to calculate the standard deviation (SD) for the three 
experimental replicates. Only the experiments with SD < 0.4 for each group of replicates were 
considered The relative expression levels for the target genes in T1AM treated respect to T1AM 
untreated tissues were calculated by geNorm method and reported as fold increase or decrease. 
One- and two-tailed Wilcoxon signed rank tests were applied to evaluate the statistical 
significance of RT-qPCR results by using a threshold p-value ≤ 0.05. 
 
 
Table 2. Housekeeping genes, target genes and RT-qPCR primers. 
 
 
 
Housekeeping genes 
Gene 
Symbol 
RefSeq mRNA Forward Primer Reverse Primer Ta 
Mapk6 NM_031622.2 5’- GCCACACAAACCGCTGAC -3’ 5’- CCGTTGGGAAAGAGTAGATGC -3’ 58°C 
Kdm2b NM_001100679 5’- GCAAGCAAGTCACCAAGG -3’ 5’- TCGTTTCAGATTCCAAAGGG -3’ 58°C 
Psmd4 NM_031331 5’- AGATGATGCCCTACTGAAGATGAC -3’ 5’- GACGCTCTGAAGGAACTCTGG -3’ 58°C 
Cypa NM_017101   5’- CAAGACTGAGTGGCTGGATGG -3’ 5’- GCTACAGAAGGAATGGTTTGATGG -3’ 58°C 
B2mg NM_012512 5’- TCAAGTGTACTCTCGCCATCC -3’ 5’- GCAAGCATATACATCGGTCTCG-3’ 58°C 
Bact NM_31144 5’- CCACACCCGCCACCAGTTC-3’ 5’- GACCCATACCCACCATCACACC -3’ 60°C 
Target genes 
Gene 
Symbol 
RefSeq mRNA Forward Primer Reverse Primer Ta 
Scarb1 NM_031541 5’- GCAGTGATGATGGAGGACAAGCC -3’ 5’- GAAGACGGTGAAGACGCCAGAAC -3’ 62°C 
Hdlpb NM_172039.2 5’- CCATTGCGGTAGAGGTGAAG -3’ 5’- ACGGTGAAGCCAGGAAGG -3’ 58°C 
Igfbp2 NM_013122 5’- CCTCTGGAACATCTCTACTC -3’ 5’- ACTGGCTGTGGTTTACTG -3’ 58°C 
Ascl5 NM_053607 5’- TGGGATGCTGGGTGTTTG -3’ 5’- TACTTCCTGTGTCTTCTCTGG -3’ 58°C 
Apod NM_012777 5’- AGTTGAGGGTGAAGCCAAACAGAG -3’ 5’- GCAGGAATACACGAGGGCATAGC -3’ 62°C 
Cebpb NM_024125 5’-ATCGACTTCAGCCCCTACCT-3’ 5’-GGCTCACGTAACCGTAGTCG-3’ 60°C 
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RESULTS 
 
MICROARRAY RESULTS 
T1AM chronic administration altered the gene expression in rat subcutaneous adipose tissue. 
Specifically, 378 genes were differentially expressed, 268 up-regulated and 110 down-regulated. 
Due to the limited information on pathways and gene functional annotations currently retrievable 
from databases, only a small group of genes was mapped by Pathway Express. Specifically, 
Pathway Express placed 60 differentially expressed genes in 70 pathways (table 3).  
To identify other genes that might have an important role in T1AM molecular mechanism of 
action, the list of differentially expressed genes was further investigated by an accurate screening 
of the scientific literature. By using the information included in OntoExpress, GeneCards, 
PubGene and Coremine bioinformatics tools other 20 genes implicated in relevant mechanisms 
were identified (table 4).  
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Table 3. The 70 pathways containing  the 60 genes mapped by Pathway Express. 
 
 
 
 
 
 
 
 
 
 
 
 TGF-beta signaling pathway 
 Neuroactive ligand-receptor  
 interaction 
 mTOR signaling pathway 
 Jak-STAT signaling pathway 
 Cell adhesion molecules 
(CAMs) 
 Wnt signaling pathway 
 VEGF signaling pathway 
 Phosphatidylinositol signaling     
 system 
 MAPK signaling pathway 
 Hedgehog signaling pathway 
 ErbB signaling pathway 
 ECM-receptor interaction 
Calcium signaling pathway 
ENVIRONMENTAL 
INFORMATION PROCESSING 
 
  Vascular smooth muscle  
  contraction 
  Toll-like receptor signaling  
  pathway 
  T cell receptor signaling  
  pathway 
  Renin-angiotensin system 
  Olfactory transduction 
  Natural killer cell mediated  
  cytotoxicity 
  Melanogenesis 
  Long-term potentiation 
  Long-term depression 
  Leukocyte transendothelial  
  migration 
  Insulin signaling pathway 
  GnRH signaling pathway 
  Fc gamma R-mediated  
  phagocytosis 
  Fc epsilon RI signaling pathway 
  Complement and coagulation  
  cascades 
  Circadian rhythm 
  Chemokine signaling pathway 
  B cell receptor signaling  
  pathway 
  Axon guidance 
  Antigen processing and  
  presentation 
  Adipocytokine signaling 
  pathway 
ORGANISMAL SYSTEMS 
  Type II diabetes mellitus 
  Thyroid cancer 
  Small cell lung cancer 
  Renal cell carcinoma 
  Prostate cancer 
  Primary immunodeficiency 
  Pathways in cancer 
  Parkinson's disease 
  Pancreatic cancer 
  Non-small cell lung cancer 
  Melanoma 
  Hypertrophic cardiomyopathy  
  (HCM) 
  Glioma 
  Endometrial cancer 
  Colorectal cancer 
  Chronic myeloid leukemia 
  Bladder cancer 
  Basal cell carcinoma 
  Amyotrophic lateral sclerosis  
  (ALS) 
  Alzheimer's disease 
  Acute myeloid leukemia 
HUMAN DISEASES 
Tight junction 
Regulation of autophagy 
Regulation of actin cytoskeleton 
Gap junction 
Focal adhesion 
Endocytosis 
Apoptosis 
Adherens junction 
CELLULAR PROCESSES 
 Ubiquitin mediated proteolysis 
 Spliceosome 
 RNA degradation 
 Proteasome 
 Non homologous end-joining 
 Basal transcription factors 
 Aminoacyl-tRNA biosynthesis 
GENETIC 
INFORMATION PROCESSING 
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Table 4. Genes identified using the information contained in OntoExpress, GeneCards, PubGene and Coremine 
bioinformatics tools. 
 
RT-QPCR RESULTS 
In order to validate the microarray results, six genes differentially expressed between T1AM 
treated and untreated rats were selected for the RT-qPCR analysis: Scarb1, Acsl5, Hdlbp, Apod, 
Igfbp2, and Cebpb. All these genes were chosen both for their p-value and biological relevance. 
The differential expression was confirmed for Igfbp2, Acsl5, Scarb1 and Apod genes. Cebpb 
showed the same trend of differential expression evidenced by microarrays but without reaching 
any statistical significance. The differential expression of Hdlbp was opposite to that observed 
by microarrays and not statistically significant (figure 6). 
 
 
 
 
 
 
 
Genes Fold-Change direction 
Ldlrap1 (LDL receptor adaptor protein 1) ↑ 
Lrp10 (low-density lipoprotein receptor-related protein10) ↑ 
Apod (Apolipoprotein D) ↑ 
Scarb1 (scavenger receptor class B, member 1) ↑ 
Sirt6 (sirtuin 6) ↑ 
Lipoprotein functions 
Osbpl5 (oxysterol binding protein-like 5) ↑ 
Adra2c (adrenergic, alpha-2C-, receptor) ↓ 
G0s2 (G(0)/G(1) switch gene 2) ↓ 
Acsl5 (acyl-CoA synthetase long-chain family member 5) ↑ 
Lipolysis  
and   
Beta-oxidation 
Pex5 (peroxisomal biogenesis factor 5 ) ↑ 
Stat5b (signal transducer and activator of transcription 5B)  ↑ 
Cebpb (CCAAT/enhancer binding protein (C/EBP), beta) ↓ 
Pmp22 (peripheral myelin protein 22) ↑ 
Sirt2 (sirtuin 2) ↑ 
Nolc1 (nucleolar and coiled-body phosphoprotein 1)  ↓ 
Igfbp2 (insulin-like growth factor binding protein 2) ↓ 
Dmpk (dystrophia myotonica-protein kinase) ↑ 
Apln (apelin),  ↓ 
Paqr3 (progestin and adipoQ receptor family member III ) ↑ 
Adipogenesis 
Pla2g2a (phospholipase A2, group IIA (platelets, synovial 
fluid)  ↓ 
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Figure 6. The differential expression of six genes, observed by microarrays, was checked by RT-qPCR. Changes in 
gene expression were confirmed for four of these genes: Igfbp2, Acsl5, Scarb1 and Apod.  The trend of differential 
expression evidenced by microarrays was confirmed for Cebpb but not for Hdlbp gene. 
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DISCUSSION 
 
T1AM slows down the metabolism by blocking carbohydrate utilisation and promoting lipid 
consumption (Braulke et al. 2008). The molecular mechanism by which T1AM favours lipid over 
glucose catabolism is not known. However  considering the lasting effects of T1AM on fatty acid 
metabolism (Braulke et al. 2008), it is reasonable to expect that the observed shift in energy 
utilization arises from changes in gene expression. 
In order to investigate the molecular mechanisms underlying the metabolic effects of T1AM, 
gene expression profiles were analyzed in the subcutaneous adipose tissue of eight rats 
chronically treated with T1AM as compared with eight untreated rats..  
Three hundreds and 78 genes resulted differentially expressed. Sixty of them were mapped in 70 
pathways by Pathway Express. This limited number of mapped genes depends on the fact that 
the information currently present in KEGG (Kyoto Encyclopedia of Genes and Genomes), the 
genomic bank on which Pathway Express relies, is still incomplete. 
Of the 70 retrieved pathways, as metabolic pathways are not included in Pathway Express, only 
three, contribute to explain the T1AM effect on metabolism: the adipocytokine signalling 
pathway, the insulin signalling pathway and the phosphatidylinositol signalling pathway. In 
addition, many of these pathways were identified by just one mapped gene, which makes their 
actual regulation by T1AM difficult to prove.. 
As a result the pathway analysis was integrated with data obtained by OntoExpress, GeneCards, 
PubGene and Coremine bioinformatics tools. This made it possible to identify other 20 genes 
implicated in molecular mechanisms relevant to the T1AM metabolic effect. 
 
T1AM UP-REGULATES GENES RELATED TO LIPOPROTEIN FUNCTION 
Lipoproteins are delegated to transport lipids, which are insoluble in blood, in the circulatory 
system. They are spherical particles with a core composed of cholesterol esters (CE) and 
triacylglicerols. Their surface is composed of amphiphilic proteins and lipids whose outward-
facing surfaces are water-soluble and inward-facing surfaces are lipid-soluble. Most of the 
adipocyte cholesterol originates from circulating lipoproteins (Yu, Zhao and Hu 2010).  De novo 
synthesis of cholesterol is, in fact, low in the adipose tissue, as observed in early studies which 
reported that the rate of cholesterol synthesis in fat cells is only 4% of that of liver (Kovanen, 
Nikkilä and Miettinen 1975).  
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Some genes regulated by T1AM are related to lipoprotein function and five of them are  of 
particular interest: Ldlrap1 (LDL receptor adaptor protein 1), Lrp10 (low-density lipoprotein 
receptor-related protein10), Apod (Apolipoprotein D), Scarb1 (scavenger receptor class B, 
member 1), Sirt6 (sirtuin [silent mating type information regulation 2 homolog] 6).  
The Ldlrap1 product is an adaptor protein required for efficient endocytosis of low density 
lipoprotein receptor (LDLR), which plays a crucial role for the removal of circulating LDLs 
(Low Density Lipoproteins) (Michaely et al. 2004). LDLs are the main cholesterol-transporting 
lipoproteins in plasma (Mahley et al. 1984). The protein encoded by this gene stabilizes the 
association between LDLR and LDL and  promotes the internalization of the LDL-LDLR 
complex (Michaely et al. 2004). 
Alterations in the bond between LDL and LDLR impede the endocytosis of the complex and 
lead to an accumulation of LDL in plasma. Elevated plasma levels of LDL are a key risk factor 
for the onset of coronary artery disease (Ross 1986). 
Lrp10 belongs to the LDLR family and its product mediates the cellular uptake of VLDLs (Very 
Low Density Lipoproteins) remnants in vitro (Sugiyama et al. 2000). VLDLs are lipoproteins 
produced by the liver, rich in triglycerides and relatively poor in cholesterol. Nascent VLDLs are 
released from the liver into the bloodstream and the triglycerides are hydrolysed by lipoprotein 
lipase (LPL). The released fatty acids are used by the adipose and muscle tissues for storage or 
energy production. The VLDLs, depleted of triglycerides and enriched with cholesterol, are 
called VLDL remnants and are degraded by the liver. Sugiyama and colleagues demonstrated 
that LRP10, through the interaction with apoE which is abundant in the VLDL remnants, is 
involved in their blood clearance (Sugiyama et al. 2000). Lrp10 is also a molecular target of 
Ginko Biloba that is known to have cholesterol-lowering effect (Xie et al. 2009).  
Apod is an apolipoprotein structurally similar to the lipocalin family proteins that is responsible 
for lipid transport. A reduced Apod expression alters the lipid metabolism (Perdomo and Henry 
Dong 2009). Plasma Apod  is a component of HDLs (High Density Lipoproteins) involved in the 
“reverse cholesterol transport” by which the cholesterol is transferred from peripheral tissues to 
the liver for biliary excretion  (Mahley et al. 1984). Apod modulates the activity of 
lecithin:cholesterol acyltransferase (LCAT), an HDL-bound enzyme that catalyzes the 
conversion of free cholesterol to CE that is then recruited into the HDL core. An increase in the 
cholesterol esterification by LCAT is observed in presence of Apod and the formation of Apod-
LCAT complex has a stabilizing effect on LCAT (Steyrer and Kostner 1988).  By enhancing the 
cholesterol esterification through LCAT, Apod indirectly promotes the reverse cholesterol 
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transport (Rassart et al. 2000). Moreover, a covalent cross-link between Apod and Apoa-II, a 
structural component of HDL, has been identified (Blanco-Vaca et al. 1992). 
In the adipocytes, Apod is a target for liver X receptor (LXR) that recognizes cellular cholesterol 
in excess (Hummasti et al. 2004, Lehmann et al. 1997). In particular, LXR protects the cells from 
cholesterol accumulation, by the activation of the reverse cholesterol transport (Crestani et al. 
2004).  
The Scarb1 gene codifies an HDL transmembrane receptor that mediates CE transfer from 
plasma HDL to tissues without HDL particle degradation (CE selective up-take) (Acton et al. 
1996). The protein has horseshoe-like membrane topologies with a large extracellular loop 
anchored to the plasma membrane at both the N- and C- extremities (Krieger 2001). 
HDL-Scarb1 interaction induces the formation of an hydrophobic channel by which the HDL 
unloades the CE.  The cholesterol-depleted HDL comes off the receptor and re-enters in circle to 
capture other molecules of peripheral cholesterol (Trigatti, Rigotti and Krieger 2000). 
Given that Scarb1 regulates the cholesterol levels into plasma HDL, its decrease has been 
associated with increased susceptibility to atherosclerosis: Scarb1 KO mice show elevated HDL 
cholesterol plasma levels and reduced selective HDL cholesterol clearance(Rigotti et al. 1997, 
Out et al. 2004). In addition, the distruption of Scarb1 gene in atherosclerotic mice (APOE -/-) 
accelerates the onset of atherosclerosis (Trigatti et al. 1999). These studies suggest a protective 
effect of Scarb1 toward atherosclerosis.  
Sirt6 codifies a member of sirtuin family that has NAD-dependent deacetylase and ADP-
ribosyltransferase activities (Blander and Guarente 2004, Haigis and Guarente 2006, Liszt et al. 
2005). It has been recently observed that transgenic mice overexpressing Sirt6 and fed with high 
fat diet accumulate significantly less LDL-cholesterol compared with their wild–type littermates 
(Kanfi et al. 2010). 
To summarize, T1AM, by modulating the expression of genes related to lipoprotein function, 
seems to affect the cholesterol homeostasis. This hypothesis is corroborated by the upregulation 
of another gene, Osbpl5 (oxysterol binding protein-like 5) which codifies a member of the 
oxysterol-binding protein (OSBP) family that controls the oxysterol activity (Beh et al. 2001). 
The oxysterols, oxygenated derivatives of cholesterol, are particularly potent inhibitors of 
cholesterol biosynthesis (Gill, Chow and Brown 2008).  
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T1AM REGULATES GENES RELATED TO LIPOLYSIS AND BETA-OXIDATION 
Lipolysis hydrolyzes triglycerides and releases glycerol and free fatty acids. It is a catabolic 
process that provides energy to the adipose tissue when needed. Some genes related to lipolysis, 
like Adra2c (adrenergic, alpha-2C-, receptor) and G0s2 ((G(0)/G(1) switch gene 2)) are down-
regulated by T1AM.  
Adra2c is a target of catecholamines that are important regulators of fat cell lipolysis (Langin 
2006). Sustained lipid mobilization and an increase in energy expenditure were observed during 
administration of an alpha2-adrenoceptor antagonist in dogs and humans (Lafontan and Berlan 
1995, Berlan, Montastruc and Lafontan 1992).  
The G0s2 protein negatively regulates the activity of the adipose triglyceride lipase (ATGL), 
which catalyzes the first step in the hydrolysis of triglycerides. G0s2 protein binds directly to 
ATGL and reduces ATGL-mediated lipolysis by inhibiting its hydrolase activity (Yang et al. 
2010). In Hela cells, the G0S2 over-expression prevents the ATGL-mediated lipid droplet 
degradation as well as basal and stimulated lipolysis in cultured adipocytes, whereas the down-
regulation of endogenous G0S2 enhances adipocyte lipolysis (Yang et al. 2010). 
In addition, T1AM up-regulates the expression of genes linked to beta-oxidation, like Acsl5 
(acyl-CoA synthetase long-chain family member 5) and Pex5 (peroxisomal biogenesis factor 5).  
In the cytoplasm, the free fatty acids coming from lipolysis are converted to acyl-CoA thioesters 
by the acyl-CoA synthetases (ACSs). Then, they are directed toward the de novo lipid synthesis 
to store energy or toward beta-oxidation both in mitochondria and in peroxisomes to produce 
ATP (Achouri et al. 2005).  ACSs are classified based on their preference for short, medium, 
long and very long chain fatty acids (Coleman et al. 2002b). Long-chain ACSs (ACSLs) modify 
fatty acids long 12-22 carbons (Li 2006). The Acsl5 is the only ACSL isoform known to be 
located on the mitochondrial outer membrane and has a probable role in the beta-oxidation of 
fatty acids (Coleman et al. 2002a). In support of this hypothesis an increase of Acsl5 protein and 
mRNA after food deprivation has been observed (Lewin et al. 2001). Moreover, Acsl1 and Acsl4 
but not Acsl5 are inhibited by Triascin C (Kim, Lewin and Coleman 2001) that blocks the de 
novo triglyceride synthesis (Igal, Wang and Coleman 1997). This suggests that Acsl5 is not 
linked to the triglyceride synthesis. 
The Pex5 gene codes a protein involved in the biogenesis of peroxisomes, which are organelles 
where the initial steps of beta-oxidation of very long chain fatty acids occur (Varanasi et al. 
1996, Mannaerts, Van Veldhoven and Casteels 2000). These data suggest that T1AM promotes 
both triglyceride lipolysis and beta-oxidation, according to an increased lipid utilisation. 
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T1AM REGULATES THE EXPRESSION OF GENES RELATED TO ADIPOGENESIS 
The amount of body fat depends on several factors that affect both the size and the number of 
adipocytes. Besides mature adipocytes, the adipose tissue contains multipotent mesenchymal 
cells and pre-adipocytes able to proliferate after specific stimuli (Bon 2008). If the food intake 
exceeds the energy consumption, the mature adipocytes go towards hypertrophy (increase in 
size) and hyperplasia (increase in number) (Bon 2008). The hypertrophy arises from triglyceride 
accumulation in existing adipocytes. The hyperplasia, also known as adipogenesis, comes from 
recruitment, proliferation and differentiation of pre-adipocytes (Hausman et al. 2001).  
Several transcription factors, including members of the C/EBP family, are induced during the 
adipocyte differentiation and play an important role in the regulation of adipocyte gene 
expression (Rosen et al. 2002). Cebpb, for example, down-regulated by T1AM, is the first player 
in adipogenesis, being responsible of C/EBPalfa and PPARgamma activation (Miyaoka et al. 
2006, Rosen et al. 2002).  
The adipocyte gene expression is also affected by Signal Transducers and Activators of 
Transcription (STATs) (White and Stephens 2010). Stat5b, up-regulated by T1AM, is activated 
in the early phase of the differentiation process and is a positive regulator of proliferation 
(Nanbu-Wakao et al. 2002). However, a continuous and excessive activation of Statb becomes 
inhibitory for the adipogenesis (Miyaoka et al. 2006). 
Many other genes regulated by T1AM, including Pmp22 (peripheral myelin protein 22), Sirt2 
(sirtuin [silent mating type information regulation 2 homolog] 2), Nolc1 (nucleolar and coiled-
body phosphoprotein 1) and Igfbp2 (insulin-like growth factor binding protein 2, 36kDa) are 
implicated in the adipogenesis. 
Pmp22, up-regulated by T1AM, belongs to the Growth Arrest Specific (GAS) gene family. The 
genes of this family regulate the cellular growth by blocking the mitotic division in response to 
extracellular signals (Schneider, King and Philipson 1988). In mice 3T3-L1, during the pre-
adipocyte maturation, the GAS genes are upregulated and the Pmp22 gene exerts an inhibitory 
effect on adipogenesis (Shugart et al. 1995).  
Sirt2, up-regulated by T1AM, codifies a member of the sirtuin family. In mouse 3T3-L1 pre-
adipocytes, the Sirt2 overexpression inhibits the adipocyte differentiation (Jing, Gesta and Kahn 
2007). Conversely, Sirt2 downexpression promotes the adipogenesis (Jing et al. 2007). Sirt2 
suppresses the adipogenesis by deacetylating FOXO1, which ties PPARgamma and represses its 
transcriptional activity (Jing et al. 2007).  
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Nolc1, down-regulated by T1AM, codifies a member of the retinoblastoma family. These 
proteins are phosphorilated by cyclins to promote cell proliferation in a variety of cells (Claudio, 
Tonini and Giordano 2002). In the adipose tissue, the cell proliferation is stimulated by FGF10 
through the activation of the Ras/Map pathway followed by the cyclin D2-dependent NOLC1-
phosphorylation (Konishi et al. 2006). 
Igfbp2, down-regulated by T1AM, codifies a member of the IGF binding protein family that 
sequesters the IGFs in the extracellular environment and limits their access to the signalling 
receptors (Baxter and Twigg 2009). In particular, Igfbp2 inhibits the IGF1-IGF1R interaction by 
sequestering IGF1 (Baxter and Twigg 2009) that is an inducer of pre-adipocyte differentiation 
(MacDougald and Lane 1995). Whether Igfbp2 exerts an inhibitory effect on pre-adipocyte 
differentiation by sequestering IGF1 is unknown (Baxter and Twigg 2009), but it has been 
recently observed that mice overexpressing Igfbp2 have an increase in fat mass compared to 
their nontransgenic littermates (Rehfeldt et al. 2010). These data raise the hypothesis that T1AM 
controls the adipose tissue expansion by inhibiting adipogenesis.  
The up-regulation of Dmpk (dystrophia myotonica-protein kinase) gene, instead, might 
contribute to control the adipose tissue increment by reducing the adipocyte hypertrophy. This 
gene encodes a serine/threonine protein kinase, whose deficiency appears to be a risk factor for 
adiposity. Dmpk KO mice fed with high-fat diet, in fact, exhibit increased body weight and fat 
mass compared to wild type mice. This increase in adipose tissue mass correlates with the 
adipocyte hypertrophy (Llagostera et al. 2009). 
 
Finally, given that the adipose tissue expansion requires the formation of new vessels, 
(Christiaens and Lijnen 2010, Rupnick et al. 2002, Hausman and Richardson 2004) the 
regulation of angiogenesis-related genes, like Apln (apelin), Paqr3 (progestin and adipoQ 
receptor family member III) and Pla2g2a (phospholipase A2, group IIA platelets, synovial fluid) 
might represent a molecular mechanism by which T1AM inhibits the adipogenesis. 
Apln gene, down-regulated by T1AM, encodes a peptide binding the APJ receptor (Tatemoto et 
al. 1998) and promotes angiogenesis in several tissues (Cox et al. 2006, Brooks, Clark and 
Cheresh 1994, Sorli et al. 2007). Kunduzova and colleagues demonstrated that the apelin/APJ 
signalling pathway promotes the angiogenesis also in the adipose tissue (Kunduzova et al. 2008). 
It has been proposed that the block of apelin signalling decreases angiogenesis and adiposity 
(Rayalam et al. 2008). 
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Paqr3 gene, up-regulated by T1AM, codifies an adiponectin receptor (Garitaonandia et al. 2009) 
that has been reported to inhibit the angiogenesis by suppressing the VEGF signalling both in 
vitro and in vivo  (Zhang et al. 2010). 
Pla2g2a gene, down-regulated by T1AM, codifies a phospholipase that catalyzes the sn-2 acyl- 
hydrolysis of phospholipids, thus causing the liberation of arachidonic acid that can be used to 
produce eicosanoids (Dennis 1997, Mayer and Marshall 1993). The Pla2g2a inhibition has been 
shown to reduce the formation of capillary-like tubes(Chen et al. 2004). 
 
CONCLUSIONS 
 
The results of this study suggest that T1AM controls the adipose tissue expansion by regulating 
genes linked to lipid metabolism, adipogenesis and angiogenesis. The observed changes in gene 
expression also contribute to explain the long lasting effects of T1AM on energy production, 
caused by a shift from carbohydrates to lipid metabolism. These findings furthermore suggest 
that T1AM represents a good candidate for obesity treatment. In fact, not only it does not show 
the same negative side effects of thyroid hormones, but also influences the expression of genes 
able to control the blood cholesterol level.  This provides new insights for the T1AM action, like 
i.e. a protective role against atherosclerosis and coronary disease. These hypotheses are worthy 
to be further investigated by functional studies in vitro  and in vivo.. 
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